Novel drug approved for multiple myeloma
the ONA take:
The U.S. Food and Drug Administration has approved Farydak (panobinostat) in combination with bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior standard therapies, including an immunomodulatory agent like thalidomide or lenalidomide and bortezomib.
“Farydak has a new mechanism of action that distinguishes it from prior drugs approved to treat multiple myeloma, making it a potentially attractive candidate agent for the treatment of multiple myeloma,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Farydak’s approval is particularly important because it has been shown to slow the progression of multiple myeloma.”
The most common side effects associated with Farydak were diarrhea, nausea, decreased appetite, peripheral edema, vomiting, tiredness, and weakness. The most common laboratory abnormalities were hypokalemia, hypophosphatemia, hyponatremia, anemia, thrombocytopenia, and leukopenia.
According to the American Cancer Society's estimates, there will be about 26,850 new cases of multiple myeloma in the United States in 2015 and about 11,240 deaths.
The FDA has approved Farydak (panobinostat) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|